Clevegen – pharmaceutical daily

February 21, 2019 Off

Faron Pharmaceuticals opens two UK sites to expand Matins trial, testing its cancer immunotherapy Clevegen

Faron Pharmaceuticals said Thursday in a press release that it is currently opening two UK sites (London, Birmingham) to expand the Matins trial, following recent CTA approval by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA).

July 25, 2016 Off

Faron and Abzena in cancer medicine Clevegen manufacture deal

By Dino Mustafić

Faron and Abzena in cancer medicine Clevegen manufacture deal

November 30, 2015 Off

Faron: Clevegen can be used as immunotherapy product

By Dino Mustafić

A publication on Clever-1 function related to Faron Pharmaceuticals’ novel cancer immunotherapy antibody Clevegen, was published in journal of the American Association of Immunology.

November 3, 2015 Off

Faron Pharmaceuticals secures Clevegen production with Swiss Selexis

By Dino Mustafić

Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.